Adaptimmune raises $104 million to develop immune-system cancer drugs-Reuters
British biotechnology company Adaptimmune has raised $104 million in venture capital to fund its work in developing a new range of drugs based on immune-system cells, Reuters reported.
25 September 2014•2 mins read
